TY - JOUR T1 - e0442 Effect of aspirin and cilostazol on inflammatory cytokines in patients with acute coronary syndrome JF - Heart JO - Heart SP - A137 LP - A138 DO - 10.1136/hrt.2010.208967.442 VL - 96 IS - Suppl 3 AU - Hao Tang AU - Jingguo Wu AU - Qing Yang AU - Zhongfu Ma Y1 - 2010/10/01 UR - http://heart.bmj.com/content/96/Suppl_3/A137.3.abstract N2 - Objective To investigate the effect of aspirin and cilostazol on interleukin-6 (IL-6) and high sensitive C reactive protein (hsCRP) and platelet-activating factor acetylhydrolase (PAF-AH) in acute coronary syndrome (ACS) patients and the difference between them. Methods 72 patients with ACS were randomly divided into two groups: the aspirin group (n=34) and cilostazol group (n=38). All patients were given routine therapy including rest, oxygen inhaling, anticoagulating, reducing blood lipid levels, controlling the blood pressure. The patients in the aspirin group were given aspirin 0.1 g every day in addition. The patients in the cilostazol group were given cilostazol 0.1 g twice a day underlying the routine therapy. The course of treatment was 4 weeks. Observe the IL-6 and hsCRP and PAF-AH in serum and on peripheral blood mononuclear cells of the patients before and after treatment. Result The basic characteristics of the two groups were identical (p>0.05). The content of IL-6 and hsCRP were all significantly decreased after therapy (p<0.05), and the content of PAF-AH were significantly increased after therapy (p<0.05). The content of IL-6 (25.9±7.5 vs 20.3±9.8 pg/ml) and hsCRP (9.5±2.1 vs 6.1±1.9 g/l) in aspirin group (after treatment) were significantly higher than those in cilostazol group (after treatment)(p<0.05), and PAF-AH (27.2±5.6 vs 36.8±2.6 μmolċmin−1l−1) in aspirin group (after treatment) were significantly lower than those in cilostazol group (after treatment) (p<0.05). Conclution Aspirin and cilostazol can decrease IL-6 and hsCRP level and increase PAF-AH level in ACS patients. And cilostazol is more effective than aspirin to inhibit the inflammatory response in ACS patients. ER -